Fintech PR
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
- Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate
- Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million)
LONDON, Feb. 1, 2024 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group). This extension brings the total raised in Series B financing to £31.1m (approx. USD $39.5m).
NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (‘MMR’) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore’s first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.
2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC in Boston in October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.
The additional Series B funding will be used to progress NeoPhore’s lead oral program, through early pre-clinical development.
Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”
Dr Robert James, Chairman of NeoPhore, said: “Over the past years NeoPhore has made tremendous strides in showing that it is possible to target the MMR pathway with small molecule inhibitors. The recent data the Company has generated and presented at an international conference leads us to believe that NeoPhore’s approach may be profoundly important. We are pleased to welcome three new Italian-based investors to our syndicate as well as further funding from existing investors. Their commitment reflects the potential value of NeoPhore’s approach that exploits the dynamics of cancer neoantigen evolution, through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. We are very excited about the next stage in the life of the Company.”
About NeoPhore Ltd
NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit www.neophore.com
About NEVA SGR
Neva SGR, venture capital arm of the Intesa Sanpaolo Group and wholly owned by the Intesa Sanpaolo Innovation Center, plans and manages investment funds for professional investors interested in seizing diversification and high-yield opportunities offered by Venture Capital investments. Neva SGR can count on Intesa Sanpaolo Innovation Center’s and Intesa Sanpaolo Group’s strength, financial resources, know-how and network of relationships, a unique source of value on the market. Neva SGR can watch trends and markets from a privileged position and takes action with the strength and the responsibility of Italy’s leading banking group. Intesa Sanpaolo Innovation Center has invested in Neva First, the investment fund designed for excellent, high-tech, high-innovation start-ups, which take advantage of trends with exponential growth potential.
To learn more visit www.nevasgr.com
About LIFTT
Chaired by the scientist and entrepreneur Stefano Buono, LIFTT’s aim is to encourage technology development and transfer from University to Industry, but also to clear the way from a simple business idea to the creation of an innovative product, offering a dynamic and modern vision of venture capital as applied to Technology Transfer. To date, LIFTThas raised EUR 103,5 million and has completed 47 investments, from a pipeline of +3000 companies, operating in all market sectors, with a particular focus on Deep Tech. www.liftt.com Head of Communications & Investor relations: [email protected]
About Simon Fiduciaria
Simon Fiduciaria is the fiduciary and trust company of Ersel Group which since 1936 has been a specialist in wealth management and a unique company in Italy for its absolute independence, professionalism, quality of service, and direct and personal relationship with the client.
Founded in 1986, Simon Fiduciaria stands out for its independence as well as its operational and professional qualities, to fully meet the needs of its customers. As a reference point for the Italian fiduciary market, with over 7 billion administered assets, Simon Fiduciaria has developed, alongside fiduciary and trust heading services, an innovative service dedicated to large private and institutional assets, with independent and analytical monitoring that offers an aggregated view of allocation, performance, and risks, and highlights potential areas for improvement.
About Sixth Element Capital LLP and the CRT Pioneer Fund
Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC’s experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programmes in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development.
For more information, please see www.sixthelementcapital.com
About Claris Ventures
Claris Ventures is a biotech-focused venture capital firm based in Turin (Italy). Its first fund under management, Claris Biotech I, was launched in 2020 to finance high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international. We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients’ needs, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy.
http://www.clarisventures.com/
About 3B Future Health Fund II
3B Future Health Fund II S.C.A. SICAV-RAIF is a Luxembourg based investment fund investing in oncology and rare disease therapeutics in Europe and the United States. The firm’s goal is to identify innovative and promising companies that are developing First-in-Class therapeutics for indications with high unmet patient needs and provide them with the financial resources and strategic guidance they need to succeed. The fund targets companies with strong management teams, a solid scientific foundation, and a clear path to regulatory approval and commercialization. We seek to invest in early-stage companies with promising preclinical data. Additionally, the fund’s investment team has extensive experience in the pharma industry, a track record of success in drug development and identifying high-potential investments. 3B is committed to creating value for its investors while also making a positive impact on the lives of patients. For more information please see www.3bfuturehealth.com
About Astellas Venture Management LLC
Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. (Astellas) to accomplish the strategic goals. The venture capital activity of AVM is designated since 2005. Astellas, the ultimate parent company of AVM, headquartered in Tokyo is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products”. Through strategic investments in private early-stage companies, the funds aim to mutual-interact with Astellas, leading to partnering/collaboration in the future. AVM will be able to provide portfolio companies with invaluable R&D advice and assistance.
About 2Invest
2Invest AG (2Invest) is an investment company listed on Frankfurt market formed in 2020 from the restructuring of businesses of 4basebio AG. Our investment objective is primarily but not exclusively to identify and support emerging companies with both strong management teams and ground-breaking technologies in the biotechnology, life sciences and IT sectors. Our ambition is to enable those companies to reach new and meaningful value inflexion points.
View original content:https://www.prnewswire.co.uk/news-releases/neophore-raises-an-additional-9-6m-usd-12-2m-series-b-financing-extension-to-further-progress-drug-discovery-pipeline-302049681.html
Fintech PR
Grexie Signchain Launches on November 1st, 2024: Enabling Smart Contract Developers to Bring Off-Chain Data On-Chain with Seamless Gas-Paid Signing
Grexie Signchain enables developers to sign off-chain data into smart contracts, with self-hosted or secure vault signer wallet management.
MANCHESTER, England, Oct. 17, 2024 /PRNewswire/ — Grexie Limited proudly announces the launch of its innovative smart contract solution, Signchain, on November 1st, 2024. Designed specifically for developers, Signchain introduces a powerful way to bring off-chain data on-chain through user-paid gas fees and secure signing of data into smart contract methods using its extendable smart contract, Signable.
In the growing landscape of blockchain technology, securely managing off-chain data and integrating it into on-chain smart contracts has posed significant challenges for developers. Signchain eliminates these hurdles by offering a robust, gas-efficient system for signing and authenticating data in real-time.
Key Features of Signchain:
1. Seamless Off-Chain to On-Chain Data Integration
Signchain enables developers to securely bring off-chain data on-chain by signing it directly into smart contract methods through user-paid gas fees. This integration ensures that data authenticity is preserved, and its entry into the blockchain remains tamper-proof, streamlining processes for industries relying on real-world data verification. Signchain also supports integration with Google Sheets, AWS, and Firebase, making it easy to pull data from popular off-chain data sources.
2. Extendable Smart Contract – Signable
The core of Signchain’s technology is its extendable smart contract, Signable, which allows developers to customize and build upon existing smart contracts. With Signable, developers can easily implement contract signatures for any data type, offering flexibility across industries from finance to logistics and beyond.
3. Signer Wallet Management
Signchain offers comprehensive signer wallet management as part of its service, empowering developers to manage and authenticate signers effectively. Wallets can either be self-hosted using Signchain’s Docker container for those who prefer their own infrastructure, or they can leverage Signchain’s network of secure vaults for maximum security.
4. Self-Hosted or Managed Service
For developers who want full control of their infrastructure, Signchain provides a self-hosted option via Docker containers, allowing them to deploy the platform on their own servers. Alternatively, developers can opt to use Signchain’s secure vault network, offering a hassle-free solution with enterprise-grade security and wallet management.
5. User-Paid Gas Fees
By integrating a user-paid gas fee model, Signchain allows users to cover the costs of signing and authenticating their data, ensuring the signing process is efficient and doesn’t overburden developers with additional expenses. This makes Signchain an ideal solution for dApps and platforms handling high transaction volumes.
6. Google Sheets, AWS, Firebase Integration with Serverless Model
Signchain supports integration with Google Sheets, AWS, and Firebase in a serverless model, powered by a hosted Sign In With Ethereum (SIWE) implementation provided by Signchain’s API. Developers can simply connect their Google Sheets and configure the contract parameters associated with each column. Signchain will automatically look up the user’s wallet address in the spreadsheet, sign the transaction data, and execute it in the blockchain along with any user-supplied parameters. This creates an easy, efficient way to manage data inputs from off-chain sources without heavy infrastructure setup.
Revolutionizing Smart Contract Workflows
With Signchain, developers now have the tools to handle the complexities of integrating off-chain data into smart contracts. The extendable nature of Signable offers flexibility, allowing developers to cater to various use cases, whether it’s automating financial transactions, supply chain data, or verifying legal agreements.
Tim Behrsin, CEO of Grexie Limited, said, “Signchain is more than just a signing solution—it’s a platform that empowers developers to securely integrate off-chain data into their smart contracts with minimal effort. The flexibility of Signable and our focus on signer wallet management offers developers control and security at every stage of the process.”
Why Signchain Matters
Signchain addresses critical challenges faced by developers, particularly those dealing with off-chain data. By signing data into smart contracts and enabling user-paid gas fees, the platform significantly reduces friction in managing secure, scalable smart contracts. Whether developers need to manage high volumes of data transactions or create bespoke smart contracts, Signchain offers a scalable and secure solution.
In industries like DeFi, real estate, and supply chain management, data integrity and security are paramount. Signchain’s secure vault network and customizable signing workflows allow businesses to handle sensitive information with confidence.
Launch Event and Future Developments
The official launch of Signchain will take place on November 1st, 2024, alongside a virtual event. The event will showcase live demonstrations of Signable, with detailed walkthroughs of the Docker-based self-hosted solution and signer wallet management features. Attendees will also get an exclusive preview of future enhancements, including multi-signature workflows and advanced blockchain network integrations.
About Signchain
Signchain is a cutting-edge platform developed by Grexie Limited, based in Manchester, Cheshire, United Kingdom. Signchain simplifies smart contract development by offering a secure, scalable, and customizable solution for signing and authenticating off-chain data on-chain. Developers can either self-host the solution using Signchain’s Docker container or rely on the network’s secure vault infrastructure. With an emphasis on security, flexibility, and developer experience, Signchain is set to transform how smart contracts handle off-chain data.
For more information, visit signchain.net.
Logo – https://mma.prnewswire.com/media/2533672/Signchain_Logo.jpg
Photo – https://mma.prnewswire.com/media/2533843/Signchain_flow.jpg
PDF – https://mma.prnewswire.com/media/2533539/Signchain_Whitepaper.pdf
View original content:SOURCE Grexie Limited
OXFORD, England, Oct. 17, 2024 /PRNewswire/ — n2 Group, the transformative computing technology investment company, announces the acquisition of high-performance computing (HPC) and AI specialists, X-ISS. The addition of X-ISS expands the Group’s portfolio– joining NAG, VSNi, BioTeam and STAC—as it accelerates advancements in technology and computation, underpinned by innovation, technical excellence, and a focus on long-term growth.
n2 Group invests selectively in technical computing companies with deep business impact in a variety of sectors, providing operational support and a collaborative approach to innovation and business transformation. The addition of X-ISS will further strengthen the Group’s already strong HPC/AI credentials, with NAG, STAC and BioTeam already adding to this space.
X-ISS is a pioneer in Managed Services specifically designed for HPC/AI. With their in-depth understanding of hardware and software complexities within HPC and AI, they deliver highly impactful end-to-end services to clients through the integration, optimization and management of HPC/AI systems. The integration of X-ISS into n2 Group aligns with the Group vision of improving the accessibility, quality and robustness of computing solutions to enable greater productivity in industry.
X-ISS will operate as an autonomous business within the n2 Group, maintaining its brand, identity and ethos. n2 Group’s status as an independent, member-backed organisation with no external financial stakeholders allows X-ISS to continue providing impartial advice based on the technology needs and challenges of its clients. Inter-group synergies will enable greater innovation and collaboration, advancing the Group’s position and long-term HPC/AI market impact.
“X-ISS strengthens the n2 community in the strategically important area of HPC/AI”, said Adrian Scales, Snr Director of Investments and Partnerships at n2 Group. “As a respected boutique HPC service provider, X-ISS is helping clients navigate an increasingly complex landscape in terms of technologies and software integrations with AI and analytics. The acquisition strongly complements the Group’s existing HPC professional services capability, and we are delighted to have them on board.”
“This is an important milestone for X-ISS.”, said Deepak Khosla, CEO X-ISS, “The partnership with n2 Group will enable us to enhance our flagship ManagedHPC solution by leveraging n2‘s complementary services and product developments, allowing us to deliver even greater value to our customers. As businesses face increasing challenges with complex technologies like AI and cloud computing, we’re now better equipped to support them with the same quality, passion, and partnership that defines X-ISS. I am excited about the opportunities this can bring for current and future X-ISS customers.”
About n2 Group
At n2 Group we are transforming computing and technology investment with a radical new approach. Our businesses are all established, purpose-driven market-leaders in computing products or services. We stimulate long-term sustainable growth through group-level support in strategy, business development, innovation, and operations. With no shareholders or external financial interests, we reinvest all profits back into the group or to the community, reinforcing our commitment to positive social impact through technological advancements.
n2 Group companies are at the forefront of computing and IT infrastructure, helping clients in various sectors to be more productive, innovative or reduce risk through advanced software and services. Rapidly expanding in high-performance computing, artificial intelligence, and scientific computing, our businesses maintain their unique brands and identities, but benefit from the expanded network available through the group.
n2 Group Companies
• BioTeam: Scientific computing consultancy integrating technologies, data, and cultures to accelerate science.
• NAG: Advanced products and services in algorithms, optimization, high-performance computing and AI.
• STAC: Independent financial services technology research and community events.
• VSNi: Proven statistical solutions and data expertise driving innovation and success.
• X-ISS: Industry leading management and analytics solutions for HPC/AI systems.
For more detailed information and the latest updates, visit n2 Group.
Logo – https://mma.prnewswire.com/media/2271328/n2_Group_Logo.jpg
Logo – https://mma.prnewswire.com/media/2533549/XISS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/n2-group-advances-hpcai-portfolio-by-acquiring-managed-services-company-x-iss-302279433.html
SAN ANTONIO, Oct. 17, 2024 /PRNewswire/ — AIMed24, the premier event for artificial intelligence and healthcare innovation, is excited to announce its strategic partnership with Frost & Sullivan. This collaboration will further enhance AIMed24’s mission to advance healthcare with cutting-edge AI technologies. The conference will take place from November 17-19, 2024, at the Caribe Royale Orlando.
With over 60 years of supporting client growth, Frost & Sullivan has established itself as a leader in growth strategy and innovation through its unique Ecosystem of Content, Community, and Coaching. Frost’s Growth Pipeline as a Service (GPaaS) empowers companies, governments, and investors to maximize their economic potential while navigating emerging trends and pursuing sustainable growth. This partnership aligns perfectly with AIMed24’s focus on future-proofing healthcare through innovation.
Dr. Anthony Chang, founder of AIMed and Chief Intelligence and Innovations Officer at Children’s Hospital of Orange County, said, “Partnering with Frost & Sullivan brings immense value to AIMed24. Their expertise in fostering growth and innovation across industries, including healthcare, complements our mission to lead the conversation on AI’s transformative impact on patient care. Together, we’re shaping the future of medicine with pioneering ideas and real-world solutions.”
Greg Caressi, Senior Vice President of Global Client Services at Frost & Sullivan, shared his enthusiasm, stating, “We are thrilled to partner with AIMed24, a conference that has consistently brought together the brightest minds in AI and healthcare. This partnership aligns with our commitment to creating opportunities for sustainable growth and innovation, and our focus on AI in healthcare and life sciences applications. We look forward to contributing to the exchange of knowledge that will inspire the next wave of healthcare advancements.”
AI Med, a leading event that brings together experts at the intersection of artificial intelligence and healthcare, will serve as a platform for Greg Caressi to share his deep expertise in digital health transformation and AI-driven healthcare innovations. As a recognized thought leader in healthcare technology and innovation, Greg has spent decades analyzing emerging trends and fostering strategic initiatives that enhance data transformation and utilization of data to drive health outcomes.
AIMed24 is the must-attend conference for healthcare professionals, AI innovators, and technology leaders. With strategic partnerships like Frost & Sullivan, this year’s event promises to deliver an immersive experience, featuring groundbreaking keynote speakers, hands-on workshops, and unparalleled networking opportunities. The collaboration highlights AIMed’s global impact, with representation from all five continents and over 50 countries throughout its history. Attendees will have the opportunity to learn from industry experts and gain insights into AI’s role in shaping the future of healthcare.
Why This Partnership Matters: AIMed24 is committed to building long-term partnerships with key organizations that share its vision of improving healthcare through AI. Frost & Sullivan’s expertise in identifying growth opportunities and their forward-looking approach to industry trends makes them an ideal partner. Together, AIMed24 and Frost & Sullivan will deliver a unique, high-value experience for attendees, ensuring they leave equipped with actionable strategies and insights to drive AI innovation in healthcare.
Scholarships and Global Representation: AIMed24 is proud to continue its tradition of supporting clinicians and students from around the world through special scholarships. This initiative ensures that financial barriers do not prevent the brightest minds from participating in this world-class event.
Register Today: Don’t miss out on AIMed24! To learn more about the event and secure your tickets, visit www.aimed.events.
About Frost & Sullivan
For over six decades, Frost & Sullivan has guided the world’s top companies toward transformational growth journeys that result in a stream of innovative growth opportunities. Frost’s Growth Pipeline as a Service (GPaaS) value proposition allows customers to maximize their economic potential, navigate emerging megatrends, and shape a future based on sustainable growth. Learn more.
About AIMed24
AIMed24 is where AI and medicine’s brightest minds converge to shape the future of healthcare. Join us at the Caribe Royale Orlando from November 17-19 for groundbreaking keynotes, hands-on workshops, and exceptional networking opportunities with industry leaders.
Founded by Dr. Anthony Chang, AIMed is a clinician-led community advancing AI in health. AIMed24 will showcase impactful smart healthcare solutions, facilitate connections with AI trailblazers, and engage with top institutions and innovators.
Be at the forefront of healthcare innovation. Learn more.
View original content:https://www.prnewswire.co.uk/news-releases/press-announcement-aimed24-announces-strategic-partnership-with-frost–sullivan-302279447.html
-
Fintech PR7 days agoBybit Doubles Down on Rewards for Late Entrants of WSOT 2024 With New 100,000 Prize Pool
-
Fintech PR7 days agoVantage Markets Adds Another Feather to its Cap: Wins Best Forex Affiliate Program at Global Brand Awards 2024
-
Fintech PR7 days agoRSM US and RSM UK pursue transatlantic merger to strengthen global client offering and deliver long-term growth
-
Fintech PR6 days agoBybit x Block Scholes Derivatives Report Uncovers BTC Call Option Boom Amidst Election Uncertainty
-
Fintech PR7 days agoOCI to Close Divestment of Controlling Stake in Fertiglobe
-
Fintech PR7 days agoBitget Launches Telegram App Centre, Featuring Over 600 TON Trending Mini-Apps
-
Fintech PR7 days agoBingX Launches Telegram Mini App for Seamless Copy Trading
-
Fintech PR5 days agoStatement regarding revised possible cash offer from ABC Technologies Inc. and extension of Rule 2.6 deadline